Download Files:
EFdA-TP (tetrasodium)
SKU
HY-138561B-1 mg
Category Reference compound
Tags Anti-infection;Cell Cycle/DNA Damage, DNA/RNA Synthesis;HIV;Reverse Transcriptase, Infection
$780 – $3,180
Products Details
Product Description
– EFdA-TP tetrasodium is a potent nucleoside reverse transcriptase (RT) inhibitor. EFdA-TP tetrasodium inhibits RT-catalyzed DNA synthesis as an effective immediate or delayed chain terminator (ICT or DCT). EFdA-TP tetrasodium inhibits HIV-1 RT with multiple mechanisms[1]. EFdA-TP (tetrasodium) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Web ID
– HY-138561B
Storage Temperature
– -20°C (Powder, sealed storage, away from moisture and light)
Shipping
– Blue Ice
Applications
– COVID-19-anti-virus
Molecular Formula
– C12H11FN5Na4O12P3
References
– [1]Martin Markowitz, et al. 4′-Ethynyl-2-fluoro-2′-deoxyadenosine, MK-8591: a novel HIV-1 reverse transcriptase translocation inhibitor. Curr Opin HIV AIDS. 2018 Jul;13(4):294-299.|[2]Eleftherios Michailidis, et al. 4′-Ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms. J Biol Chem. 2014 Aug 29;289(35):24533-48.
CAS Number
– 2883783-00-2
Molecular Weight
– 621.12
Compound Purity
– 95.18
SMILES
– O=[P](O[P](O[P](O[Na])(O[Na])=O)(O[Na])=O)(O[Na])OC[C@]1(O[C@@](C[C@@H]1O)([H])N2C3=NC(F)=NC(N)=C3N=C2)C#C
Clinical Information
– No Development Reported
Research Area
– Infection
Solubility
– 10 mM in DMSO
Target
– DNA/RNA Synthesis;HIV;Reverse Transcriptase
Isoform
– HIV-1
Pathway
– Anti-infection;Cell Cycle/DNA Damage
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.